probiotics

we are probiotic makers™

Clinically studied probiotic portfolio

probiotics
probiotics.saccoystem.com

Supporting food cultures and life since 1872
saccosystem.com

SACCO system

Gastrointestinal (GI) Health

Irritable Bowel Syndrome (IBS)	PENTABIOCEL®	Reduces the severity of IBS-type symptoms in coeliac disease patients on a strict gluten free diet by improving gliadin hydrolysis (a gluten protein mainly involved in the allergic burden felt by patients)	20 Bn CFU per day
Broad spectrum blend for Adult gastrointestinal relief	SYNBIO®	A patented blend: WO 2005/095656 A1 and EP 1 743 042 B1 Microbiota Balance in Adults 18 - 90 years of age Relief in Constipation, Flatulence, Abdominal pain, Gut Inflammation and Bloating. Improved ease of defecation and transit time Successfully colonizes the gut, competing with and reducing harmful bacteria as well as enhancing bowel habits and well-being Supports regrowth of Bifidobacteria	1 Bn to 5 Bn CFU per day
Neonatal GI support Children's GI support Adults GI support	*B. coagulans* SNZ 1969™	Improved watery stools in Neonatal infants within 1 to 2 days Improved gastroenteritis in Children up to 3 years of age within 3 days Improves gut motility and constipation in healthy adults with habitual low intake of fruit and vegetables Relief from gas, heartburn, and bloating in Adults Heat stable strain, can be exposed to temperatures up to 140 degrees C. Room Stable CFU count for 3 years.	15 Mn to 2 Bn CFU per day
Children's Gastrointestinal support and immunity	*L. rhamnosus* CRL 1505™	Significantly decreases intestinal infections CRL 1505 reduces acute diarrhoea and the use of antibiotics	100 Mn CFU per day
Adherent-Invasive Escherichia coli (AIEC) reduction	*L. acidophilus* LA1™ *L. paracasei* 101/37™ *B. animalis ssp lactis* Bi1™ *B. breve* BBR8™	Some inflammatory bowel diseases can be triggered by AIEC. With scientific in-vitro testing, all probiotic strains were shown to impair adhesion of AIEC to human epithelial cells All probiotic strains were able to show reduced survival of AIEC and invasion of HT-29 cells	In-vitro
GI Infections and Diarrhoea	*L. rhamnosus* GG(ATCC53103)™	"World's most researched Probiotic strain Strong gastrointestinal adhesion Suitable for Gut Health products for Infants, children and adults Used in Antibiotic associated diarrhoea products Improved abdominal pain in Children Supports gastrointestinal immunity and microflora balance"	2 Bn to 20 Bn CFU per day

Gut Brain Axis

Mental health	*L. reuteri* PBS072™ *B. breve* BB077™	Improved mood state within 30 days treatment. Reduced feeling of tension, anxiety and anger due to workplace stress. Sleep quality improved with statistical significance P<0.01. Students taking the supplement showed a better intellectual responsiveness under pressure by improving attention. Improved flexibility to make decisions and support short-term memory	4 Bn CFU per day

Women's Intimate Health

Vaginal Health	SYNBIO®	A patented blend: WO 2005/095656 A1 and EP 1 743 042 B1 Significant inhibition of growth of known vaginal pathogens. Clinically researched in oral capsule delivery, topical pessary and in-vitro use This blend will support a dual microbiome product reducing a women's bloating, abdominal pain, and constipation in the GI microbiome, whilst also reducing symptoms of vaginal itching, reduction in pathogens in the vagina such as enterococci, staphylococci, Gardnerella vaginalis, Candida and E. coli Clinically proven to restore vaginal pH and reduce vaginal discharge Produces H_2O_2	5 Bn CFU per day
	B. coagulans SNZ 1969™	Treatment in both oral and topical dose forms Reduction in recurrent bacterial vaginosis Effective against non-specific vaginitis	150 Mn CFU per day
	L. plantarum LB931™	Vaginally isolated L. plantarum Topical human clinical study in vaginal health Lowered mean vaginal pH Inhibited group B streptococci In-vitro reduction of Candida Albicans In-vitro inhibition of E. coli"	500 Mn CFU per day
	L.fermentum CS57 ™	Vaginally isolated L. fermentum Secretes a bacteriocin-like substance (BLS) with antagonistic activity against Streptococcus agalactiae and Candida albicans. Produces H2O2	1 Bn CFU per day
	L.rhamnosus CA15™	Isolated from the vaginal tract of a healthy woman Antagonistic activity against Urinary Tract Infection pathogens Clinically studied for Vaginal Microbiome balance with treatment time at 10 days	10 Bn CFU per day
	L. crispatus BC5™	Vaginally isolated strain from healthy women Researched In sexually transmitted diseases Fungicidal activity against Candida isolates 100% In-vitro Inhibition of Neisseria gonorrhoeae (GC) Extensive antifungal, antibacterial and antiviral activities	1 Bn CFU per day
	L. gasseri BC12™	Vaginally isolated strain from healthy women Researched In sexually transmitted diseases 100% In-vitro Inhibition of Neisseria gonorrhoeae (GC) Extensive antifungal, antibacterial and antiviral activities	1 Bn CFU per day

Immune Health

Upper Respiratory Tract Immunity	*L. rhamnosus* CRL 1505™	CRL 1505 reduces the incidence of upper respiratory tract infections (URTI) and gastrointestinal infections in children, supporting the immune system and reducing the need for antibiotics, whilst also reducing the number of lost school days due to illness. In human clinical trials CRL 1505 boosted IgA production by 43% Reduced episodes of infection with Respiratory Syncytial Virus (RSV) Reduce diarrhoea incidences Reduced pharyngitis and tonsilitis	100 Mn CFU per day
Adult Cold and Flu	SYNBIO®	SYNBIO showed statistically significant improvement in Adult Cold and improvement in feeling tired	2 Bn CFU per day

Contact us to know product's availability in your market

Oral Health

Dental Caries (Tooth Cavities)	*L. rhamnosus* SP 1™	Regular intake reduces the occurrence of dental caries	1.5 Bn CFU per day
	L. rhamnosus LB21™	Reduces caries development and the number of days with antibiotic treatment by 60% in preschool children	1.5 Bn to 2 Bn CFU per day
	B. coagulans SNZ 1969™	Significantly reduction of the cariogenic microorganism Streptococcus mutans in children	150 Mn CFU per day
Halitosis	*K. marxianus fragilis* B0399™	Improves adult halitosis by reducing volatile sulphur compounds through GI system	10 Mn CFU per day
Periodontitis	*L. rhamnosus* SP 1™	Studied side by side with Azithromycin antibiotic. L. rhamnosus SP 1 resulted in similar clinical and microbiological improvements in Adult Periodontitis compared to the placebo group, but SP 1 reduced the need for surgery	20 Mn CFU per day
Aphthous Ulceration	*B. coagulans* SNZ 1969™	Significantly reduces the incidence of recurrent mouth (aphthous) ulcers	150 Mn CFU per day
Oral health in Denture use	*L. rhamnosus* SP 1™	Reduction in Candida associated denture stomatitis in Senior adults 62 - 98 years of age Adults in the probiotic group showed significant improvement in reduction of Candida lesions and reduction in oral inflammation	2 Bn CFU per day

Allergy & Skin Health

Skin Health: Adult Acne	*L. rhamnosus* SP 1™	Reduces Acne in Adults Improves the appearance of acne and lessens the inflammatory processes related to acne formation by modulating genes implicated in insulin signaling	3 Bn CFU per day
Atopic Dermatitis	*L. rhamnosus* LB21™	Significantly reduces the need to use corticosteroids in infants and young children	100 Bn CFU per day
	L. rhamnosus LB21™ and *L. rhamonsus* SP 1™	Topical application decreases severity of eczema signs and intensity of itching on people with atopic dermatitis	1 Bn CFU per day
	K. marxianus fragilis B0399™	The major hallmark of atopic dermatitis (AD) is the elevated level of total serum IgE. B0399 improves atopic dermatitis by decreasing IgE levels to normality	10 Mn CFU per day
Dust Mites causing Rhinitis	SYNBIO®	Significantly reduces allergic sensitisation to House Dust Mites, which are a leading cause of rhinitis	15 Bn CFU per day

Sport

Performance Improvement during endurance sports	SYNBIO®	Improves the body's recovery processes and tiredness sensation after training by lowering exercise-induced oxidative stress. In addition, SYNBIO® improves gastrointestinal functions and reduces susceptibility to illness	2 Bn CFU per day

Aged Care

Healthy Aging	SYNBIO®	Successfully studied in Senior adults aged 65 - 90 years of age. SYNBIO® successfully proven to be an INFLAMMAGING ™ probiotic blend by: Effecting cytokine modulation Reducing the circulating levels high-sensitivity C-reactive protein (HsCRP). Improvement in nutritional status Improvement in psychological wellbeing	5 Bn CFU per day
Oral health in Denture use	*L. rhamnosus* SP 1™	Reduction in candida associated denture stomatitis in Senior adults 62 - 98 years of age Adults in the probiotic group showed significant improvement in reduction of Candida lesions and reduction in oral inflammation	2 Bn CFU per day

Weight Loss

Metabolic health	*L. plantarum* IMC 510™	After 12 weeks of supplementation, Probiotic users recorded a drop in body weight, reduction in waist circumference and also a drop in Body Mass Index (BMI) This trend continued 30 days after supplementation stopped. Lactobacilli and Bifidobacteria counts increased in the GI System leading to increased healthy bowel habits	15 Bn CFU per day

Postbiotics

Heat-inactivated whole bacteria	*L. acidophilus* LA1 H.I.™ *L. plantarum* 14D H.I.™ *L. casei* BGP93 H.I.™ *B. animalis ssp. lactis* BLC1 H.I.™ *B. longum* SP 54™	Beneficial for Food companies and health food companies looking for new trends in consumer marketing Limited overage needed Able to feature in more food and drink formats than live strains	1 Bn CFU per day
Respiratory health	*L. rhamnosus* CRL 1505 H.I.™	Mouse model scientifically studied for protection against Respiratory Syncytial Virus (RSV). Nasally administered powder, triggering Toll-like Receptor 3 (TLR3) activation to increase resistance to RSV	100 Mn CFU per day
Leaky Gut and Inflammation	*L. paracasei* D3-5™	Mouse model scientifically studied for preventing high-fat diet-induced metabolic dysfunctions, decreases leaky gut and inflammation, and improves physical and cognitive functions. Whilst also improving Akkermansia muciniphila cell counts. Mechanism of action is through Lipoteichoic acid from the cell wall of the bacteria	5 Bn CFU per day

Children and Infant Health

Infant Colic	*L. reuteri* LR92™	Clinically researched in pregnant women for the relief of colic in newborn infants Infants born to mothers in the Probiotic group suffered 2.6x less episodes of Infant colic than the infants who's mothers were in the placebo group	100 Mn CFU per day
Upper Respiratory Tract Immunity Gastrointestinal Immunity Ear Infection (Otitis media)	*L. rhamnosus* CRL 1505™	CRL 1505 reduces the incidence of upper respiratory tract infections (URTI) and gastrointestinal infections in children, supporting the immune system and reducing the need for antibiotics, whilst also reducing the number of lost school days due to illness. In human clinical trials CRL 1505 boosted IgA production by 43% Reduced episodes of infection with Respiratory Syncytial Virus (RSV) Reduce diarrhoea incidences Reduced pharyngitis and tonsilitis	100 Mn CFU per day
Otitis Media (Middle Ear Infection)	*L. rhamnosus* LB21™ *L. rhamnosus GG* (ATCC 53103)™	Otitis Media is the most common childhood infection LB21 and GG Probiotic strains reduce the incidence of Otitis Media in Children	1.5 Bn CFU per day
Diarrhoea Rotaviral Diarrhoea Gastroenteritis	*B. coagulans* SNZ 1969™	Up to 94% effectiveness in treatment of diarrhoea in Infants (Neonatal) within 3 days	5 Mn CFU per kilo per day for 5 days

Probiotic manufacturing at Sacco System

SACCO SYSTEM

Via A. Manzoni, 29/A
22071 Cadorago CO

CSL

Strada Provinciale per Merlino, 3
26839 Zelo Buon Persico LO

CSL USA

Nicholson Road, 4011
Franksville, WI 53126
United States



we are probiotic makers™

Services

Custom Fermentation Service

We are able to support you from strain development to large scale commercial manufacturing in our cutting-edge probiotic facilities.

Turn-Key Solutions

We realize that every customer has specific needs, but all willing the best quality. We provide integrated solutions using a global network of reliable CMO partners.